Raloxifene
Also known as: Raloxifene, Raloxifen, Evista, Raloxifene HCl
The SERM used when tamoxifen fails against gynecomastia — it binds the breast tissue receptor more strongly, and it is the last option before surgery.
Substance family
Selective estrogen receptor modulators. They block the receptor in some tissues while leaving it active in others — which is why they restart the hormonal axis and protect breast tissue without lowering estradiol itself.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance works against
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Established gynecomastia (off-label)
Medical (off-label)Dose
60 mg / day
Frequency
1× daily
Cycle length
3–6 months
Studied in adolescent gynecomastiagynecomastiaGrowth of actual breast gland tissue in men — not fat, and not reversible once established., where it outperformed tamoxifen in reducing breast tissue volume. That is the basis for its use here — it is the option when tamoxifen has not worked.
Alongside a cycle
Not a recommendationDose
—
Frequency
—
Cycle length
—
Raloxifene does not lower estradiolestradiolThe main estrogen — needed in men too, and damaging in both directions when out of range.; it blocks the receptor in breast tissue. Taking it preventively addresses no measured problem and does nothing about the estradiol level itself. If estradiol is genuinely high, an aromatase inhibitoraromatase inhibitorA drug that blocks the conversion of testosterone to estradiol. is the tool for that.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Blood clot risk
Countermeasure
The most serious concern, and it is documented in the approval trials: raloxifene increases the risk of venous thromboembolism. That matters disproportionately here, because androgens already raise hematocrithematocritThe percentage of blood made up of red cells — rises on androgens and thickens the blood. and thicken the blood. Anyone with a raised hematocrit, a clotting history, prolonged immobility or upcoming surgery should treat this as a genuine contraindication rather than a footnote.
Problem
It does not lower estradiol
Countermeasure
Like tamoxifen, raloxifene blocks the estrogen receptor rather than reducing the hormone. EstradiolEstradiolThe main estrogen — needed in men too, and damaging in both directions when out of range. on a blood test does not fall — it may rise. That is expected and does not mean it is failing. Someone whose actual problem is a high estradiol level needs an aromatase inhibitoraromatase inhibitorA drug that blocks the conversion of testosterone to estradiol. instead, or as well.
Problem
Timing decides the outcome
Countermeasure
GynecomastiaGynecomastiaGrowth of actual breast gland tissue in men — not fat, and not reversible once established. responds to SERMsSERMsA drug that blocks the estrogen receptor in some tissues while activating it in others. while the tissue is still developing and inflammatory. Once it has become fibrotic — firm, painless, established over months — no drug removes it and surgery is the only option. The window is measured in weeks, which is why the first sign of tenderness is when to act.
Problem
Weaker on the axis than tamoxifen
Countermeasure
Raloxifene has less effect on LH and FSH, so it is a poorer choice for restarting the axis in a PCTPCTThe protocol after a cycle intended to restart the body's own testosterone production.. That is a division of labour rather than a flaw: tamoxifen or enclomiphene for recovery, raloxifene for breast tissue that has not responded.
Problem
Do not stack SERMs casually
Countermeasure
Tamoxifen and raloxifene compete for the same receptor. Taking both does not double the effect and may reduce it. Switch rather than combine.
Overview
Raloxifene occupies a narrow but genuinely important position: it is what comes after tamoxifen has not worked, and before a surgeon.
It is approved for osteoporosis and breast cancer risk reduction in postmenopausal women. Its use here rests on a specific finding — in adolescent gynecomastia, raloxifene reduced breast tissue volume more effectively than tamoxifen did.
Mechanism of Action
Like all SERMs, raloxifene blocks the estrogen receptor in some tissues while leaving or activating it in others. In breast tissue it is an antagonist, preventing estrogen from stimulating glandular growth.
Its affinity for the breast tissue receptor is higher than tamoxifen's, which is the practical argument for switching when tamoxifen has not produced a response.
What it does not do is change how much estradiol exists. The hormone is still produced, still circulating, still measurable — it simply cannot act in the tissue where the receptor is blocked. This distinction is the same one that matters for tamoxifen and DIM, and it decides whether the right tool is being used.
When It Is the Right Choice
The specific sequence is: a lump develops behind the nipple, tamoxifen is started promptly, and after several weeks there is no improvement.
At that point raloxifene at 60 mg daily is the reasonable next step, and the evidence supporting it is better than most off-label uses discussed on this site.
What it is not for is prevention. Taking a SERM during a cycle to stop gynecomastia from ever appearing addresses no measured problem, and it does nothing about estradiol itself. If estradiol is high and causing symptoms, that is what an aromatase inhibitor is for.
The Clotting Point
This deserves more weight than it usually gets in forum discussions.
Raloxifene raises the risk of venous thromboembolism — that came out of the approval trials in women and is on the label. In this population it lands on top of a hematocrit that androgens have already pushed up, which raises blood viscosity and clot risk independently.
The two together are a worse combination than either alone. Anyone reaching for raloxifene should know their hematocrit, and a hematocrit above the normal range is a reason to address that first.
The Window
The most useful thing on this page is about timing rather than drug choice.
Gynecomastia begins as glandular tissue proliferating under hormonal stimulation — active, tender, responsive to intervention. Over months it becomes fibrotic: firm, no longer painful, and no longer responsive to anything pharmacological. At that point the only remaining option is excision.
Tenderness under the nipple is the signal, and it is worth acting on immediately rather than waiting to see whether it settles.
Side Effects & Risks
- Increased risk of venous thromboembolism — the main concern
- Hot flushes
- Leg cramps
- Elevated liver values, rarely
- Estradiol unchanged or rising, which is expected rather than a failure
Blood Work & Monitoring
- Hematocrit — before starting, given the clotting interaction
- Estradiol (sensitive assay) — to establish whether the actual problem is a high level
- Total and free testosterone, LH, FSH
- Liver values (ALT, AST)
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Prescription-only medicineApproved for osteoporosis and breast cancer risk reduction in women. Use in men is off-label. |
| EU / UK | Prescription-only medicine |
| Most other jurisdictions | Prescription-only; availability varies |
| Competitive sport | Prohibited at all timesSERMs are listed by WADA under S4.2. |